Trial Profile
Safety and tolerability of Rilpivirine in combination with tenofovir and lamivudine as occupational post-exposure prophylaxis for HIV infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2016
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary) ; Rilpivirine (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 29 Dec 2016 New trial record
- 30 Oct 2016 Results presented at the IDWeek 2016